THIRD HARMONIC BIO INC (THRD)

Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors

Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave...

THRD Stock Earnings: Third Harmonic Bio Beats EPS for Q4 2023

THRD stock results show that Third Harmonic Bio beat analyst estimates for earnings per share the fourth quarter of 2023.

Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results

Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results

U.S. IND filed for THB335 with anticipated clinical trial start during 2Q’24

Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference

Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference

SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Third Harmonic Bio, Inc. (NASDAQ: THRD)

/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Third Harmonic Bio, Inc. (NASDAQ: THRD) on behalf of the company's shareholders. The...

Third Harmonic Bio is Now Oversold (THRD)

Third Harmonic appoints Christopher Murphy as CFO (NASDAQ:THRD)

Third Harmonic Bio appoints Christopher Murphy as Chief Financial and Business Officer, signaling progress towards their Phase 1 study on THB335.

Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Third Harmonic Bio, Inc. (NASDAQ: THRD)

/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Third Harmonic Bio, Inc. (NASDAQ: THRD) on behalf of the company's shareholders. The...

Third Harmonic Bio Announces Third Quarter 2023 Financial Results

Third Harmonic Bio Announces Third Quarter 2023 Financial Results

On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24 Strong financial position with...

Third Harmonic Bio says CFO Robert Ho to leave co (NASDAQ:THRD)

THRD announces CFO's departure and CSO's transition in executive positions.

Third Harmonic Bio Announces Leadership Changes

Third Harmonic Bio Announces Leadership Changes

SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave...

Third Harmonic Bio files for a mixed shelf offering of $400M (NASDAQ:THRD)

THRD filed a mixed shelf prospectus to potentially raise $400M.

Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference

Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference

SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave...

(NASDAQ:THRD)

Third Harmonic Bio press release (THRD): Q2 GAAP EPS of $0.42.

Third Harmonic Bio Announces Second Quarter 2023 Financial Results

Third Harmonic Bio Announces Second Quarter 2023 Financial Results

Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor,...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Third Harmonic Bio, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335

Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335

THB335 retains selectivity and potency of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution and physicochemical...

Third Harmonic Bio Announces First Quarter 2023 Financial Results

Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases

Third Harmonic Bio Announces First Quarter 2023 Financial Results

Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases...

Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results

Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases

Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results

Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases...